Small caps round-up: Brady, Oxford BioMedica, Densitron Tech
Brady, a provider of trading, risk management and settlement solutions to the energy, metals and commodities sectors, has said that it is in a payment dispute over software with a customer that it signed in 2011.
Brady, a provider of trading, risk management and settlement solutions to the energy, metals and commodities sectors, has said that it is in a payment dispute over software with a customer that it signed in 2011.
The firm said the customer has made payments to Brady totalling £288,000, but has "not paid a number of further amounts in line with its contractual obligations". Discussions over the payments have broken down. Brady said it believes that the software has been delivered and it has been accepted by the client, adding that it "will consider all possible legal avenues for collection of the outstanding amounts".
Oxford BioMedica, a gene-based biopharmaceutical company, posted a narrowing of pre-tax losses from £9.0m to £5.7m for the half year to the end of June. Revenue for the period fell from £4.95m to £4.44m, after margins were boosted by a fall in research and development costs, from £11.8m to £6.9m. Basic losses per share dropped from 0.88p to 0.52p. Cash at the period end fell sharply from £20.2m to £1.6m.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Densitron Technologies, an information display systems manufacturer, has reported a 6.2% decline in revenue for the half year ended June 30th, to £10.6m (2011: £11.3m). Pre-tax profit fell from £0.5m to £0.04m, while more positively the order book increased by 4.5% to £11.7m (2011: £11.2m). Earnings per share of 0.52p turned to a loss of 0.11p. The interim dividend was maintained at 0.2p per share.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
8 of the best houses for sale with annexes
The best houses with annexes – from a period property in the Lake District to a 13th-century house with a two-bedroom annexe in Saltwood, Kent
By Natasha Langan Published
-
Zelenskyy moves to appease Donald Trump – what happens now?
Ukraine’s president Volodymyr Zelenskyy is conceding ground to secure the least-worst deal possible, says Emily Hohler
By Emily Hohler Published